Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Study design for a hepatitis B vaccine trial.

E D Lustbader, W T London, B S Blumberg

    Proceedings of the National Academy of Sciences of the United States of America
    |March 1, 1976
    PubMed
    Summary

    This study proposes a novel, small-sample clinical trial design for evaluating the hepatitis B vaccine. It confirms that antibodies to the hepatitis B surface antigen significantly reduce infection risk, paving the way for efficient vaccine trials.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    LEPROMATOUS LEPROSY AND AUSTRALIA ANTIGEN WITH COMMENTS ON THE GENETICS OF LEPROSY.

    Journal of chronic diseases·2015
    Same author

    Medical survey of Rongelap people five and six years after exposure to fallout (with an addendum on vegetation).

    T. Brookhaven National Laboratory·2014
    Same author

    Part 2: Hepatitis B infection and human behavior.

    Medical anthropology·2012
    Same author

    The nature of australia antigen and its relation to antigen-antibody complex formation.

    The Journal of experimental medicine·2009
    Same author

    Serum ferritin concentration and recurrence of colorectal adenoma.

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2000
    Same author

    Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents.

    Proceedings of the National Academy of Sciences of the United States of America·1999

    Area of Science:

    • Immunology
    • Vaccinology
    • Clinical Trial Design

    Background:

    • Hepatitis B virus (HBV) infection poses a significant risk, particularly in vulnerable populations like renal dialysis patients.
    • Antibody presence against the hepatitis B surface antigen (HBsAg) is hypothesized to confer protection against HBV infection.
    • Understanding infection dynamics is crucial for developing effective prevention strategies and clinical trial methodologies.

    Purpose of the Study:

    • To propose and design a short-time, small-sample clinical trial for evaluating a hepatitis B vaccine.
    • To validate the protective role of antibodies against HBsAg using naturally acquired immunity as a model.
    • To leverage observed infection rates and time independence for an efficient trial design.

    Main Methods:

    • Verification of the protective premise by comparing HBsAg infection rates in renal dialysis patients with and without naturally acquired anti-HBsAg antibodies.
    • Analysis of infection risk over time, demonstrating an exponential decrease in uninfected probability for antibody-negative patients, indicating a constant infection risk.
    • Formulation of a clinical trial design based on time independence and observed infection rates.

    Main Results:

    • Patients with naturally acquired anti-HBsAg antibodies exhibit an extremely low risk of hepatitis B virus infection.
    • The probability of remaining uninfected decreases exponentially over time in patients lacking antibodies, suggesting a constant per-unit-time infection risk.
    • The study confirms the protective efficacy of antibodies against hepatitis B virus.

    Conclusions:

    • A novel clinical trial design is proposed, enabling efficient evaluation of hepatitis B vaccines with a small sample size and short duration.
    • This design is particularly relevant for preliminary studies demonstrating vaccine-induced antibody production and potential patient benefit.
    • The findings support the use of hepatitis B vaccines for preventing viral infection, especially in high-risk groups.

    Related Experiment Videos